Amit Bar-Or, MD, FRCPC

Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.

Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.

Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.

Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, talked about the promising potential of BTK inhibitors in treating both relapsing and progressive forms of multiple sclerosis. [WATCH TIME: 6 minutes]

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

Experts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.

Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on how to move investigative treatments for multiple sclerosis off the laboratory bench and into clinical practice.

Doctors in neurology comment on the hidden symptoms of multiple sclerosis and debate whether they should be treatment targets.

Experts in neurology comment on clinical trial design considerations and discuss novel imaging techniques and biomarkers that they consider most important to investigate for multiple sclerosis.

Bridget A. Bagert, MD, leads a discussion on the ideal patient populations for using a potential vaccine for multiple sclerosis, and the panel comments on other factors to consider when administering vaccines.

Amit Bar-Or, MD, FRCPC, discusses the potential impact vaccination against Epstein-Barr virus could play on multiple sclerosis rates, highlighting recent investigations.

Experts in neurology discuss screening and diagnostic considerations for a patient newly diagnosed with multiple sclerosis.

Bridget A. Bagert, MD, and Ahmed Obeidat, MD, PhD, examine the clinical implications of a causal link between Epstein-Barr virus and multiple sclerosis and provide insight on how to discuss this link with patients.

Lawrence Steinman, MD, discusses his recent publication, which demonstrated the causal link between Epstein-Barr virus and multiple sclerosis, highlighting key findings and conclusions.

Ahmed Obeidat, MD, PhD, comments on other viruses that have been linked to the development of multiple sclerosis and discusses how they can be both protective and detrimental.

Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on the role the Epstein-Barr virus plays in the development of multiple sclerosis, highlighting recent publications examining this link.

Scott Newsome, DO, and Lawrence Steinman, MD, discuss the pathophysiology of the interactions between viruses and the immune system and explore how this can lead to autoimmune diseases.

Lawrence Steinman, MD, provides an overview of the role viruses play in the activation of the immune system, highlighting their role in triggering neuroinflammatory conditions.